The National Pharmaceutical Pricing Authority has decided to increase the price of at least twelve essential first-line treatment drugs by at least 50 per cent, as the companies, which produce these drugs, have expressed its incapability to procure the raw materials for these drugs within the limitation of the present price cap. The decision has […]Continue Reading
